Clinical use of tumor markers in malignant neoplasms
DOI:
https://doi.org/10.5281/zenodo.14876379Keywords:
Tumor marker, Cancer, PrognosisAbstract
Tumor markers are molecules, which can be elevated in the presence of a neoplastic process, either as a host reaction or as a consequence of the tumor itself. These molecules, whose serum concentration also depends on the biological variability of the patient, are detectable in different biological fluids. A review of 27 bibliographic references was carried out in order to describe the updated clinical use of tumor markers in cancer, where sources of information from Medical Sciences were consulted. The concentration of the marker reflects the success of a therapeutic procedure such as surgery, chemotherapy. It was concluded that an increase in the value of tumor markers does not always suggest the presence of cancer; its main use is for prognosis and monitoring.
References
Reiter M, Costello J, Schwope R, Lisanti C, Osswald M. Review of commonly used serum tumor markers and their relevance for image interpretation. J Compot Assist Tomogr. 2015 [citado 18/01/2020]; 39(6): 825-834. Disponible en: https://journals.lww.com/jcat/FullText/2015/11000/Review_of_Commonly_Used_Serum_Tumor_Markers_and.1.aspx
Serrano J. Los marcadores biológicos de cáncer. Natura Medicatrix. 2001 [citado 18/01/2020]; 19(6):272-278. Disponible en: https://dialnet.unirioja.es/servlet/articulo?codigo=4989310
Bast RC, Ravdin P, Hayes DF, Bates S, Fritsche H, Jessup JM, ET AL. 2000 Update of recommendations for the use of tumors markers in breast and colorectal cancer: clinical practice guidelines, of the American Society of Clinical Oncology. J Clin Oncol. 2001[citado 18/01/2020]; 19(6): 4185-4188. Disponible en: https://ascopubs.org/doi/full/10.1200/JCO.2001.19.6.1865
Litviakov NV, Bychkov VA, Stakheeva MN, Ibragimova MK, Tsyganov MM, Gaptulbarova KA. Breast tumor cell subpopulations with expression of the OCT4 proteins. J Mol Hist.2020 [citado 18/01/2020];51(6):717-728. Disponible en: https://link.springer.com/article/10.1007/s10735-020-09917-1
Cuba. Ministerio de Salud Pública. Anuario estadístico de Cuba. La Habana: MINSAP; 2018
Hermida Lazcano I, Sánchez Tejero E, Nerín Sánchez C, Cordero Bernabé R, Mora Escudero I, Pinar Sánchez J. Marcadores Tumorales. Rev Clin Med Fam. 2016 [citado 06/01/2020]; 9(1):31-42. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1699-695X2016000100006
Lavín de Juan L. Marcadores Tumorales: Presente y Futuro. [Tesis]. [España]: Universidad Complutense; 2015. 22 p. Disponible en: https://eprints.ucm.es/id/eprint/48763/1/LAURA%20LAVIN%20DE%20JUAN%20(1).pdf
Kasper LD, Fauc AS, Hauser LS, Longo LD, Jameson JL, Loscalzo J. Harrison: Principios de Medicina Interna.19na ed. México, D.F: Mcgraw-Hill Interamerican. 2015 [citado 18/01/2020]. Disponible en: https://www.academia.edu/40121481/P_R_I_N_C_I_P_I_O_S_H_A_R_R_I_S_O_N_H_A_R_R_I_S_O_N
Noya Chaveco ME, Moya González NL, Llamos Sierra N, Morales Larramendi R, Cardona Garbey DL, Filiú Ferrera JL, Del Valle Díaz S, et al. Roca Goderich: Temas de Medicina interna. 5ta ed. La Habana: Ciencias Médicas; 2017.
Tahmasebi F, Nath R, Sokolovsky N, Scaoli J, Boley J, Mehra G, et al. Incidental Finding of Raised CA125: a Cause for Concern. Crit Care Obst Gyne. 2018 [citado 15/01/2020];5(1):3. Disponible en: https://obstetrics.imedpub.com/incidental-finding-of-raised-ca125-a-cause-for-concern.php?aid=23936
Chen F, Shen J, Wang J, Cai P, Huang Y. Clinical analysis of four serum tumors markers in 458 patients with ovarian tumors: diasnostic value of the combined use of HE4, CA125, CA19-9 and CEA in ovarian tumors. Cancer Manag Res.2018[citado 18/01/2020]; 10: 1313-1318. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968799/
Nowak M, Janas L, Stachowiak G, Stetkiewicz T, Wilczynski JR. Current clinical aplication of serum biomarkers to detect ovarian cancer. Prz Menopauzalny. 2015 [citado 18/01/2020]; 14(4):254-259. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4733894/
Vitkin N, Nersesian S, Siemens RD, Koti M. The tumor inmune contexture of prostate cancer. Front Inmunol. 2019 [citado 27/01/2020]; 10:603. Disponible en: https://www.frontiersin.org/articles/10.3389/fimmu.2019.00603/full
López Ríos L, Sánchez Montero IR, García Moreno I. Relación entre el marcador tumoral antígeno prostático específico y la mortalidad por cáncer de próstata. CCM. 2017 [citado 18/01/2020]; 21(1): 100-111. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1560-43812017000100009
Salman JW, Schoots IG, Carlsson SV, Jenster G, Roobol MJ .Prostate Specific Antigen as a tumor marker in prostate cancer: biochemical and clinical aspects. Adv Exp Med Biol. 2015[citado 18/01/2020]; 867: 93-114. Disponible en: https://link.springer.com/chapter/10.1007/978-94-017-7215-0_7
Davis AA, Pierga JY, Dirix LY, Stefan Michiels S, Alfred Rademaker A, Reuben JM, et al. The impact of circulating tumor cells (CTCs) detection in metastatic breast cancer (MBC): Implications of “indolent” stage IV disease (Stage IV indolent). J Clin Oncol. 2018[citado 18/01/2020];36(15 Suppl):1019. Disponible en: https://ascopubs.org/doi/10.1200/JCO.2018.36.15_suppl.1019
Reyes García N, Miranda Devora G. Marcadores tumorales en el cáncer de mama: CA 15-3 y antígeno carcinoembrionario. Rev Mex Mastol.2016 [citado 16/01/2020]; 6(1):9-13. Disponible en: https://www.medigraphic.com/pdfs/revmexmastol/ma-2016/ma161c.pdf
Roa I, Sánchez T, Majlis A, Schalper K. Mutación del gen K-RAS en el cáncer de colon y recto. Rev Med Chile. 2013[citado 16/01/2020]; 141(9):1166-1172. Disponible en: https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0034-98872013000900009
OncoLink Team. Tumor Markers for Colorectal Cancer. Philadelphia: University of Pennsylvania [08/09/2020; citado 28/09/2020]. Disponible en: https://www.oncolink.org/cancers/gastrointestinal/colon-cancer/treatments/tumor-markers-for-colorectal-cancer
Takahashi R, Sakamoto K, Sugimoto K, Motegi S, Tsukamoto R, Ichikawa R, et al. Significance of serum p53 antibody as a tumor marker in colorectal cancer. Dis Markers.2019 [citado 18/01/2020]; 2019: 2721876. Disponible en: https://www.hindawi.com/journals/dm/2019/2721876/
Cuba. Centro Nacional de Información de Ciencias Médicas. Biblioteca MédicaNacional. Cáncer de pulmón, tráquea y bronquios. Tratamiento y Factores de riesgo. Bibliomed. 2019[citado 25/08/2019];26(3). Disponible en: http://files.sld.cu/bmn/files/2019/03/bibliomed-marzo-2019.pdf
Wadowska K , Bil Lula I, Trembecki L, Sliwinska Mosson M. Genetic markers in lung cancer diagnosis: A review. Int J Mol Sci.2020[citado 18/01/2020];21(13):4569. Disponible en: https://www.mdpi.com/1422-0067/21/13/4569
Mora Morales E, Denis Rodríguez PB, Melo SG, Aguirre GAA. Utilidad de la inmunohistoquímica en el diagnóstico del hepatocolangiocarcinoma. Rex Mex Forense. 2018[citado 18/01/2020];3(2):47-53. Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=88021
Ibrahim Alhadi M, Kumar Chutturghoon V, Kwabena G, Zhu H, Yang Zhen T, Yang Xie H, et al. Serum Biomarkers AFP, CEA and CA19-9 combined detection for early diagnosis of hepatocellular carcinoma. Iran J Public Health. 2019[citado 18/01/2020]; 48(2):314–322. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6556181/
Gzil A, Zarębska I, Bursiewicz W, Antosik P, Grzanka D, Szylberg L. Markers of pancreatic cancer stem cells and their clinical and therapeutic implications. Mol Biol Repo. 2019[citado 18/01/2020];46(6):6629–6645. Disponible en: https://link.springer.com/article/10.1007/s11033-019-05058-1
Seufferlein T, Ettich T. Treatment of pancreatic cancer- neoadjuvant treatment in resectable pancreatic cancer (PDCA). Trasl Gastroenterol Hepatol.2019[citado 18/01/2020]; 4:21. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458347/
Jose Lahoud M, Kourie Raphael H, Antoun J, El Osta L, Ghosn M. Road map for pain management in pancreatic cancer: A review. World J Gastointest Oncol.2016 [citado 06/01/2020]; 8(8): 599-606. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980650/
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Revista HolCien
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Centro Provincial de Información de Ciencias Médicas. Universidad de Ciencias Médicas de Holguín. Cuba.
Política de acceso y distribución
El total de los artículos publicados son contribuciones de acceso abierto, que se distribuyen según los términos de la Licencia Creative Commons Atribución–NoComercial 4.0 que permite el uso, distribución y reproducción no comerciales y sin restricciones en cualquier medio, siempre que sea debidamente citada la fuente primaria de publicación.
